<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169258</url>
  </required_header>
  <id_info>
    <org_study_id>B-BR-103-023</org_study_id>
    <nct_id>NCT02169258</nct_id>
  </id_info>
  <brief_title>Routine Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty</brief_title>
  <acronym>PIROUETTEPTA</acronym>
  <official_title>Prognostic Impact of ROUtine Coronary CathETerization in Low Extremity ArTEry Disease Undergoing Percutaneous Transluminal Angioplasty (PIROUETTE-PTA Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tainan Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>E-DA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Buddhist Tzu Chi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The prevalence of significant and complex obstructive coronary artery disease (CAD) is
           high in patients who have low extremity artery disease (LEAD).

        2. Long-term prognosis of LEAD undergoing percutaneous transluminal angioplasty (PTA)
           remains poor and CAD is an independent predictor of total mortality after PTA.

        3. This prospective randomized controlled trial will evaluate the prognostic effects of
           routine versus selective coronary angiography before PTA for LEAD and elucidate the
           potential mechanism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. participants

             1. eligible participants are randomly assigned to systemic strategy or selective
                strategy

                  -  participants allocated to systemic strategy will receive routine coronary
                     angiography before PTA without a previous non-invasive stress test

                  -  subjects allocated to selective strategy will undergo non-invasive evaluation
                     of possible myocardial ischemia by using dobutamine stress echocardiography
                     (DSE) or dipyridamole thallium 201 myocardial perfusion scintigraphy (dTS)
                     followed by coronary angiography if the test is positive for ischemia

             2. participants who are not willing to be randomized will be included in the
                registration group

        2. revascularization

             1. a staged approach (myocardial revascularization first followed by PTA) and
                simultaneous approach (percutaneous coronary intervention immediately followed by
                PTA at the same time if clinically suitable) are both allowed

             2. the duration from revascularization to PTA should be within 60 days

             3. percutaneous coronary intervention is performed at the time of coronary
                angiography, using bare metal or drug-eluting stents

        3. blood sampling, genotyping, and measurement of biomarkers and microRNA

           a. bood samples (20 mL) are obtained from peripheral arteries in all study subjects
           before PTA and 10 mL after PTA and are prepared and stored for enzyme-linked
           immunosorbent assay (ELISA), genotyping and measurement of microRNAs in plasma and
           peripheral blood mononuclear cells

        4. outcome follow-up a. clinical outcomes are obtained by chart review if the patient is
           still in the hospital and followed up by clinic visit, telephone call or direct contact
           with participants or subjects' family at 30 days after indexed PTA if the patient has
           been discharged from the hospital and every 6 months thereafter
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Composite of Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>up to 48 months</time_frame>
    <description>cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and any unplanned coronary revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE between the Screening and 30 days after PTA</measure>
    <time_frame>30 days after indexed PTA</time_frame>
    <description>cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and any unplanned coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Composite of major coronary events</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>fatal or nonfatal myocardial infarction, recurrent angina pectoris, and any unplanned coronary revascularization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to death from any cause</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>total mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to congestive heart failure requiring hospitalization</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>congestive heart failure requiring hospitalization</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to any coronary revascularization</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>planned or unplanned coronary revascularization</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Selective Strategy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>non-invasive evaluation of possible myocardial ischemia by using DSE or dTS followed by coronary angiography if the test is positive for ischemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Registry</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Clinical decisions are reached by consensus of operators, patients and family as usual care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic Strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine coronary angiography before PTA without a previous non-invasive stress test</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic Strategy</intervention_name>
    <description>Significant CAD needing further revascularization is defined as patients who have luminal stenosis &gt; 70% of the major epicardial vessels and bypass graft vessel or their major branches (&gt; 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (&lt;=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.</description>
    <arm_group_label>Selective Strategy</arm_group_label>
    <arm_group_label>Systemic Strategy</arm_group_label>
    <other_name>Routine Coronary Angiography before PTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known LEAD (documented by previous angiography or sonography performed by the
             operators) admitted for elective PTA

        Exclusion Criteria:

          -  Known CAD or unstable angina within past 3 months

          -  Acute myocardial infarction within past 6 months

          -  Known CAD status posterior percutaneous coronary intervention or bypass surgery within
             past 6 months

          -  Planning to do bypass surgery for known LEAD\

          -  Pregnancy

          -  Documented active malignancy

          -  Needing emergency PTA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ting-Hsing Chao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ting-Hsing Chao, MD</last_name>
    <phone>886-6-2353535</phone>
    <phone_ext>2382</phone_ext>
    <email>chaoth@mail.ncku.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting-Hsing Chao, MD</last_name>
      <phone>886-6-2353535</phone>
      <phone_ext>2382</phone_ext>
      <email>chaoth@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Cheng-Han Lee, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Chang SH, Tsai YJ, Chou HH, Wu TY, Hsieh CA, Cheng ST, Huang HL. Clinical predictors of long-term outcomes in patients with critical limb ischemia who have undergone endovascular therapy. Angiology. 2014 Apr;65(4):315-22. doi: 10.1177/0003319713515544. Epub 2013 Dec 19.</citation>
    <PMID>24357434</PMID>
  </reference>
  <reference>
    <citation>Monaco M, Stassano P, Di Tommaso L, Pepino P, Giordano A, Pinna GB, Iannelli G, Ambrosio G. Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study. J Am Coll Cardiol. 2009 Sep 8;54(11):989-96. doi: 10.1016/j.jacc.2009.05.041.</citation>
    <PMID>19729114</PMID>
  </reference>
  <reference>
    <citation>Duran NE, Duran I, Gürel E, Gündüz S, Göl G, Biteker M, Ozkan M. Coronary artery disease in patients with peripheral artery disease. Heart Lung. 2010 Mar-Apr;39(2):116-20. doi: 10.1016/j.hrtlng.2009.07.004.</citation>
    <PMID>20207271</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>September 23, 2015</last_update_submitted>
  <last_update_submitted_qc>September 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cheng-Kung University Hospital</investigator_affiliation>
    <investigator_full_name>Ting-Hsing Chao</investigator_full_name>
    <investigator_title>Associate Professor and Attending Physician</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>percutaneous transluminal angioplasty</keyword>
  <keyword>coronary angiography</keyword>
  <keyword>revascularization</keyword>
  <keyword>gene polymorphisms</keyword>
  <keyword>microRNAs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

